These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38127218)

  • 21. ASO Author Reflections: Impact of Neoadjuvant Therapy on Survival After Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7770-7771. PubMed ID: 34028634
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.
    Oshiro T; Uehara K; Aiba T; Mukai T; Ebata T; Nagino M
    Int J Clin Oncol; 2018 Aug; 23(4):681-688. PubMed ID: 29478127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.
    Alva-Ruiz R; Truty MJ
    Ann Surg Oncol; 2022 Mar; 29(3):1592-1593. PubMed ID: 34705142
    [No Abstract]   [Full Text] [Related]  

  • 24. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
    Kamarajah SK; Dahdaleh F
    Ann Surg Oncol; 2021 Apr; 28(4):1906-1907. PubMed ID: 33389290
    [No Abstract]   [Full Text] [Related]  

  • 26. ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.
    Miyasaka Y; Nakamura M
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):739-740. PubMed ID: 31538287
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ASO Author Reflections: Impact of Neoadjuvant Chemotherapy on Exploration of Fertility Preservation.
    Crown A; Gemignani ML
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):699-700. PubMed ID: 32776189
    [No Abstract]   [Full Text] [Related]  

  • 29. ASO Author Reflections: Multimodality Therapy for Patients with Pancreatic Cancer: Neoadjuvant Therapy for All?
    da Costa WL; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3196-3197. PubMed ID: 33221979
    [No Abstract]   [Full Text] [Related]  

  • 30. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.
    Peng J; Lv J; Peng J
    Int J Colorectal Dis; 2021 Aug; 36(8):1781-1790. PubMed ID: 33760952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
    Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
    Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Author response to: Total neoadjuvant therapy in rectal cancer-improvement or overtreatment?
    Zaborowski A; Stakelum A; Winter DC
    Br J Surg; 2019 Oct; 106(11):1558. PubMed ID: 31577050
    [No Abstract]   [Full Text] [Related]  

  • 34. ASO Author Reflections: Neoadjuvant Chemotherapy Does Not Affect Short-Term Outcomes After Breast Cancer Surgery.
    Konishi T; Fujiogi M; Tanabe M; Seto Y; Yasunaga H
    Ann Surg Oncol; 2022 May; 29(5):3011-3012. PubMed ID: 34997419
    [No Abstract]   [Full Text] [Related]  

  • 35. ASO Author Reflections: Assessing the Impact of Neoadjuvant Therapy: A Real View Perspective.
    Kamarajah SK; Phillips AW
    Ann Surg Oncol; 2020 Sep; 27(9):3193-3194. PubMed ID: 32227268
    [No Abstract]   [Full Text] [Related]  

  • 36. ASO Author Reflections: Mammographic Microcalcifications in Neoadjuvant Patients: Author Reflections.
    Azam R; Lim D; Curpen B; Mulligan AM; Hong NL
    Ann Surg Oncol; 2023 Jul; 30(7):4132-4133. PubMed ID: 37120486
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
    Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
    BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASO Author Reflections: Risk for Three-Course Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
    Kubo Y; Makino T; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5908-5909. PubMed ID: 37289268
    [No Abstract]   [Full Text] [Related]  

  • 39. ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?
    Cao L; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2022 Dec; 29(Suppl 3):562-563. PubMed ID: 34405294
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.